ITRACONAZOLE (itraconazole) by Bel Air Pharmaceuticals is cytochrome p450 3a4 inhibitors [moa]. Approved for azole antifungal [epc]. First approved in 2016.
Drug data last refreshed 18h ago
Cytochrome P450 3A4 Inhibitors
Azole Antifungal
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itraconazole, Fluconazole or Efavirenz on a Single Dose of Clifutinib in Healthy Participants
Effect of a Known P-glycoprotein (P-gp) Inhibitor, Itraconazole, on the Pharmacokinetics (PK) of Engasertib
A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participants
A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder
Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy Participants
Worked on ITRACONAZOLE at Bel Air Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.